Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cambrex Corp (NYSE:CBM)

46.60
Delayed Data
As of Sep 23
 +0.30 / +0.65%
Today’s Change
29.50
Today|||52-Week Range
59.41
-1.04%
Year-to-Date
Ligand Inks CNS License Agreement with Seelos Therapeutics
Sep 23 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep 15 / Zacks.com - Paid Partner Content
The Medicines Co. to Get BARDA Funding for Infection Drugs
Sep 22 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma...
Sep 14 / Zacks.com - Paid Partner Content
Bristol-Myers Opdivo's Regulatory Application Validated in EU
Sep 21 / Zacks.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi
Sep 14 / Zacks.com - Paid Partner Content
BioDelivery Bunavail Gets Better Managed Care Positioning
Sep 20 / Zacks.com - Paid Partner Content
4 Biotech Stocks to Buy as Election Fever Rises
Sep 13 / Zacks.com - Paid Partner Content
Retired? 3 Stocks You Should Consider Buying
Sep 20 / MotleyFool.com - Paid Partner Content
Repros Seeks EU Approval for Secondary Hypogonadism Drug
Sep 13 / Zacks.com - Paid Partner Content
AstraZeneca Diabetes Drug Combination Positive in Phase III
Sep 19 / Zacks.com - Paid Partner Content
Celgene's Crohn's Disease Drug Positive in Phase Ib Study
Sep 13 / Zacks.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
Sep 15 / Zacks.com - Paid Partner Content
Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial
Sep 12 / Zacks.com - Paid Partner Content